1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

SetPoint Launches IDE Trial Of Vagus Nerve Stimulation To Treat Arthritis

 
• By Reed Miller

The randomized trial will evaluate SetPoint's bioelectronic platform in patients with moderate-to-severe rheumatoid arthritis, supported by funds secured in a recent preferred stock financing.

film x-ray both human's hands and arthritis at multiple joint

SetPoint Medical is sponsoring RESET RA, the US pivotal trial of its novel arthritis therapy, with $64m raised in a recent preferred stock financing.

SetPoint developed a proprietary vagus nerve stimulation system to amplify the immunoregulation effect of the spleen. By releasing specific neurotransmitters,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Exact Sciences’ Reveals Thinking On CRC Liquid Biopsy After Freenome Deal

 
• By Natasha Barrow

Exact Sciences has entered into an exclusive licensing agreement with Freenome, stipulating clinical benchmarks and a first-line rating in the USPSTF guidelines. Medtech Insight interviewed screening CMO Paul Limburg about CRC screening and Exact’s strategy on liquid biopsy.

Biden-Era Device Trial Snapshot Pilot Halted Amid DEI Policy Shift

 
• By Elizabeth Orr

The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

Roche Eyes 2026 FDA Nod After CE Mark For pTau181 Test To Boost Global Alzheimer’s Diagnosis

 
• By Shubham Singh

The Elecsys pTau181 test, which requires only a blood sample, provides a less invasive alternative to cerebral spinal fluid procedures. A negative result could rule out Alzheimer’s and help patients avoid further testing with CSF or PET scans.

More from R&D